AUS
NZ
UK
CA
USA
IND
Oncimmune Holdings Plc
Oncimmune Holdings Plc (LON:ONC) is a global leader in providing immunodiagnostics equipment and services, and also engages in research and development around immunodiagnostics based out of the United Kingdom.
ONC Half Year Report
On 12th February 2020, Oncimmune Holdings Plc presented its half-year report for the period ended on 30th November 2019. The company highlighted that the revenue for the period was reported to be at £0.31 million, a significant increase, as opposed to the revenue reported during H1 FY 2019, which was at £0.12 million. The primary reason was a decline in the cost of sales, which were reported at £0.36 million in H1 FY 2020 as opposed to £0.60 million in H1 FY 2019. The company spent around £1.01 million on Research & Development during the period, a significant year on year increase as opposed to H1 FY 2019 when £0.69 million was spent. The total comprehensive loss for the period after tax was reported to be at £5.79 million and the Loss per share for the period was reported to be at GBX 9.16 per share.
ONC Stock Price Performance
(Source: Thomson Reuters) Daily Chart as on 12-February-20, before the closing of the LSE Market
As on 12th February 2020, at 11:00 A.M (Greenwich Mean Time), by the time of writing this report, the Oncimmune Holdings Plc stock was trading at a price of GBX 31.87 per stock on the London Stock Exchange market, a drop in the value of 0.41 per cent or GBX 0.13 per stock, as opposed to the price of the stock on the previous trading day, which had been reported to be at GBX 32.00 per stock. The market capitalisation (M-Cap) of the stock stood at a value of GBP 20.24 million, with respect to the current market price of the stock of the company at the time of writing this report.
It has been reported that the Oncimmune Holdings Plc stock had lost around 66.28 per cent in value, in the last twelve months, since February 13, 2019, when the stock was trading at a price of GBX 94.50 per stock at the time of the close of the market. It has also been reported that the companyâs stock has lost approximately 64.59 per cent, in the last six months, in comparison with the stock price of GBX 90.00 at the time of the close of the market as on August 12, 2019. Oncimmune Holdings Plcâs stock has been reported to have lost 13.86 per cent, in last 30 daysâ time from the stock price of GBX 37.00 per stock that the stock set as on January 13, 2019.
The beta of the Oncimmune Holdings Plcâs stock has been reported to be at -0.49, giving an idea that the movement in the stock price is inversely correlated to the movement of the comparative benchmark index.
Primary Health Properties Plc
Primary Health Properties Plc (LON:PHP) is the UK based company that makes financial investments in primary healthcare, providing infrastructure and equipment around the globe.
PHP Preliminary Results
On 12th February 2020, Primary Health Properties issued its results for the period ended on 31st December 2019. The company reported that the Net rental income for the period increased by 51.4 per cent year on year and was reported to be at £115.70 million for FY 2019. Adjusted EPRA earnings also increased by 62.2 per cent and were reportedly valued at £59.7 million for the period. The adjusted EPRA earnings per share were reported at GBX 5.5 per share and had increased by 5.8 per cent as compared to the previous year. In terms of the IFRS performance for the year, the company highlighted that the IFRS loss per year stood at £71.3 million while the IFRS loss per share was reported at GBX 6.5 per share. The board of the company proposed a dividend of GBX 5.6 per share, an increase of 3.7 per cent as compared to the previous year.
PHP Stock Price Performance
(Source: Thomson Reuters) Daily Chart as on 12-February-20, before the closing of the LSE Market
As on 12th February 2020, at 11:05 A.M (Greenwich Mean Time), by the time of writing this report, the Primary Health Properties Plc stock was trading at a price of GBX 162.04 per stock on the London Stock Exchange market, an increase in the value of 0.27 per cent or GBX 0.44 per stock, as opposed to the price of the stock on the previous trading day, which had been reported to be at GBX 161.60 per stock. The market capitalisation (M-Cap) of the stock stood at a value of GBP 1.965 billion, with respect to the current market price of the stock of the company at the time of writing this report.
It has been reported that the Primary Health Properties Plc stock had gained around 39.69 per cent in value, in the last twelve months, since February 13, 2019, when the stock was trading at a price of GBX 116.00 per stock at the time of the close of the market. It has also been reported that the companyâs stock has gained approximately 25.42 per cent, in the last six months, in comparison with the stock price of GBX 129.20 at the time of the close of the market as on August 12, 2019. Primary Health Properties Plcâs stock has been reported to have gained 2.82 per cent, in last 30 daysâ time from the stock price of GBX 157.60 per stock that the stock set as on January 13, 2019.
The beta of the Primary Health Properties Plcâs stock has been reported to be at 0.26, giving an idea that the movement in the stock price, is less fickle, as against the movement of the comparative benchmark index.
Plus500 limited
Plus500 Limited (LON:PLUS) is an investment services company that engages in providing online services for the trading of Contracts of Difference (COD) across the world.
PLUS Preliminary results
On 12th February 2020, Plus500 Limited declared its preliminary (unaudited) results for the period ending on 31st December 2019. The company highlighted that the operational and financial performance during the year was decent, primarily driven by the performance of the second half of the year. The company reported that the H2 FY 2019 revenues were up by 40 per cent and were reported at US$ 206.5 million when compared with H1 FY 2019 revenues, which were reported at US $148.0 million. For FY 2019, the revenues were reported at US $354.5 million, a massive decline as compared to the revenues in FY 2018 at US $720.40 million. This was on the back of the number of new customers for the year going down by 32 per cent as compared to FY 2018. The net profit for FY 2019 was reported at US $151.7 million, a significant year on year decline, as opposed to the net profit in 2018 reported at US $379.0 million. In a respite though, the H2 2019 net profit was up by 94 per cent as against the H1 net profit, as the company showed some signs of recovery in the second half of the year.
PLUS Stock Price Performance
(Source: Thomson Reuters) Daily Chart as on 12-February-20, before the closing of the LSE Market
As on 12th February 2020, at 11:10 A.M (Greenwich Mean Time), by the time of writing this report, the Plus500 Limited stock was trading at a price of GBX 938.80 per stock on the London Stock Exchange market, an increase in the value of 3.07 per cent or GBX 28 per stock, as opposed to the price of the stock on the previous trading day, which had been reported to be at GBX 910.80 per stock. The market capitalisation (M-Cap) of the stock stood at a value of GBP 986.22 million, with respect to the current market price of the stock of the company at the time of writing this report.
It has been reported that the Plus500 Limited stock had lost around 17.14 per cent in value, in the last twelve months, since February 13, 2019, when the stock was trading at a price of GBX 1133.00 per stock at the time of the close of the market. It has also been reported that the companyâs stock has gained approximately 64.30 per cent, in the last six months, in comparison with the stock price of GBX 571.40 at the time of the close of the market as on August 12, 2019. Plus500 Limitedâs stock has been reported to have gained 0.06 per cent, in last 30 daysâ time from the stock price of GBX 938.20 per stock that the stock set as on January 13, 2019.
The beta of Plus500 Limitedâs stock has been reported to be at -0.39, giving an idea that the movement in the stock price, is inversely correlated to the movement of the comparative benchmark index.
